Skip to content

Locanabio, Inc. vs Solid Biosciences

Locanabio, Inc. logo

Locanabio, Inc.

Creating RNA-targeting gene therapies to treat devastating diseases

7 employees · est. 2016 · San Diego, United States

VS
Solid Biosciences logo

Solid Biosciences

#TogetherWeAreSolid

161 employees · est. 2013 · Boston, United States

Solid Biosciences is the older company (2016 vs 2013); Solid Biosciences is the larger of the two.

Side-by-Side Comparison

Locanabio, Inc. Solid Biosciences
Founded
2016 2013 older
Headquarters
San Diego, United States Boston, United States
Employees
7 161 larger
Industry
Biotechnology, Health Care, Health and Wellness Biotechnology, Health Care
Funding Stage
Series B Post-IPO Equity
Total Funding
$155.55M $610.30M
Funding Rounds
3 9
Services
Not tracked yet Gene Therapy Development, Clinical Trials, Research Collaborations, Licensing Opportunities, Manufacturing Infrastructure
Target Customers
Not tracked yet Patients with Rare Neuromuscular Diseases, Patients with Cardiac Diseases, Medical Researchers, Healthcare Providers, Biotechnology Collaborators
Taxonomy
RNA-targeting Gene TherapyGenetic MedicineNeurodegenerative DiseasesNeuromuscular DiseasesRare Genetic DiseasesRNA Biology +5 Precision Genetic MedicineGene TherapyRare Neuromuscular DiseasesCardiac DiseasesDuchenne Muscular DystrophyFriedreich’s Ataxia +9
Website
locanabio.com solidbio.com
Locanabio, Inc. logo

About Locanabio, Inc.

Locanabio, Inc., founded in 2016, is at the forefront of developing RNA-targeting gene therapies to address significant unmet medical needs. Their innovative approach focuses on correcting disease-causing RNA, utilizing a proprietary platform that includes advanced systems like snRNA, Cas13d, and PU...

Solid Biosciences logo

About Solid Biosciences

Solid Biosciences, founded in 2013 and headquartered in Charlestown, MA, USA, is a trailblazer in the biotechnology sector, especially in precision genetic medicine. Their motto, #TogetherWeAreSolid, reflects their commitment to advancing gene therapy solutions for rare neuromuscular and cardiac dis...

Also comparing in this category

Comparing more than these two?

Get Locanabio, Inc., Solid Biosciences and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.

How does Locanabio, Inc. compare?

A PDF of Locanabio, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Rival Readout

Comparing competitors? We do this properly.

10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.

Frequently Asked Questions

Locanabio, Inc. was founded in 2016, based in San Diego, United States, with 7 employees. Locanabio, Inc., founded in 2016, is at the forefront of developing RNA-targeting gene therapies to address significant unmet medical needs. Their innovative approach focuses on correcting disease-cau. Solid Biosciences was founded in 2013, based in Boston, United States, with 161 employees. Solid Biosciences, founded in 2013 and headquartered in Charlestown, MA, USA, is a trailblazer in the biotechnology sector, especially in precision genetic medicine. Their motto, #TogetherWeAreSolid,.
Locanabio, Inc. has raised $155.55M and Solid Biosciences $610.30M. Latest stage: Locanabio, Inc. Series B, Solid Biosciences Post-IPO Equity.
Both work in Biotechnology and Health Care.

Compare Locanabio, Inc. with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Locanabio, Inc. on 11 Sep 2024, and Solid Biosciences on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout